FDA OKs Imaging Drug Cytalux To Identify Ovarian Cancer Lesions

Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively.

from RTT - Top Story https://ift.tt/3pannbT
via IFTTT